



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

### Complete if Known

Application Number	10/074,102
Filing Date	February 12, 2002
First Named Inventor	Hector F. DeLcua
Art Unit	1626
Examiner Name	R. Gerstl - G. Shanmugam
Attorney Docket Number	960296.97206

Sheet 1 of 2

### U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
AS		US- 3,285,931	11/15/66	Huisgen	
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

### FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)				
		WO 94/02483	02/03/94	PCT		

Examiner  
Signature


Date  
Considered

11/30/05

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 801.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		<b>Complete if Known</b>			
		Application Number	10/074,102		
		Filing Date	February 12, 2002		
		First Named Inventor	Hector F. DeLcua		
		Art Unit	1626		
		Examiner Name	<del>R. Gerstl</del> G. Shamineen		
Sheet	2	of	2	Attorney Docket Number	960296.97206

OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
CS		L. Chunchatprasert, et al., "A New Synthetic Route to Pyrrolo[3,2-b]carbazoles, 1H-Benzofuro[3,2-f]indoles and 1H-[1]Benzothieno[2,3-f]indoles, J. Chem. Soc. Perkin Trans on 1779-1783 1992	
		L. Chunchatprasert and P.V.R. Shannon, "Further Observations on and Novel Products from Acid-catalyzed Indole-Pyrrole Condensations: Fomation of Pyrrolo[2,3-b]carbazoles," J. Chem. Soc. Perkin Trans on 1765-1772 1994	
		P. Dharmasena, et al., "Antitumour Heterocycles. Part 12. The Synthesis of New Hydroxypyrrolocarbazoles and Hydroxypyridocarbazoles," J. Chem. Research pp. 12-13 1998	
		O. Hankinson, "The Aryl Hydrocarbon Receptor Complex," Annu. Rev. Pharmacol. Toxicol. 35:307-340, 1995.	
		P.H. jellinck, et al., "Ah Receptor Binding Properties of Indole Carbinols and Induction of Hepatic Estradiol Hydroxylation," Biochemical Pharmacology 45(5):1129-1136, 1993.	
✓		A.J. Philips, et al., "Synthesis of Functionalized Oxazolines and Oxazoles with DAST and Deoxo-Fluor," Organic Letters 2(8):1165-1168, 2000.	
CS		L. Poellinger, Regulation fo Intracellular Dioxin (Aryl Hydrocarbon) Receptor Function by Dietary Indole Derivatives," Hormonally Active Agents in Food Symposium, pp. 121-127, 1998	

Examiner Signature		Date Considered	1/30/05
--------------------	--	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.88. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

5291049\_1.PDF

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	2	of	2
-------	---	----	---

**Complete if Known**

Application Number	10/074,102
Filing Date	February 2, 2002
First Named Inventor	Hector F. DeLuca
Group Art Unit	1645-1624
Examiner Name	B. S. V.
Attorney Docket Number	960296.97206

**OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**

OTHER PRIOR ART - NON PATENT LITERATURE		OTHER PRIOR ART - PATENT LITERATURE	
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	

A. J. Philips, et al., "Synthesis of Functionalized Oxazolines and Oxazoles with DAST and Deoxo-Fluor," Organic Letter 2(8):1165-1168, 2000.

R. Susilo, et al., "Formation of Thiazolidine-4-Carboxylic Acid Represents a Main Metabolic Pathway of 5-Hydroxytryptamine in Rat Brain," J. Neurochemistry 52(6):1702-1800, 1989

**RECEIVED**

~~SEP 12 2002~~

~~TECH CENTER 1600/2900~~

**Examiner  
Signature**

Date Considered

11/30/05

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language translation is submitted.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

**DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.

5291049\_1.PDF



PTO/SB/08B (10-01)  
Approved for use through 10/31/2002. OMB 0651-0031  
U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)		<b>Complete if Known</b>	
		Application Number	10/074,102
		Filing Date	February 12, 2002
		First Named Inventor	Hector F. DeLuca
		Group Art Unit	1845-1526
		Examiner Name	B. S. Hume
		Attorney Docket Number	960296.97206
Sheet	2	of	3

RECEIVED

NOV 26 2002

TECH CENTER 1600/2900

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
GS		Adachi, J. et al. "Indirubin and indigo are potent aryl hydrocarbon receptor ligand present in human urine". J. Biol. Chem. 276(34):31475-31478 (2001).	
		Chen, I., Safe, S., and Bjeldanes, L. "Indole-3-carbinol and diindolylmethane as aryl hydrocarbon (Ah) receptor agonists and antagonists in T47D human breast cancer cells". Biochem. Pharmacol. 51(8):1069-1076 (1996).	
		Chen, Y. H. et al. "Regulation of CYP1A1 by indolo[3,2-b]carbazole in murine hepatoma cells". J. Biol. Chem. 270(38):22548-22555 (1995).	
		Cheung, Y. L., Snelling, J., Mohammed, N. N. D., Gray, T. J. B., and Ioannides, C. "Interaction with the aromatic hydrocarbon receptor, cyp1a induction, and mutagenicity of a series of diaminitoluenes - implications for their carcinogenicity". Toxicol. Appl. Pharmacol. 139(1):203-211 (1996).	
		Garrison, P.M. et al. "Species-specific recombinant cell lines as bioassay systems for the detection of 2,3,7,8-tetrachlorodibenzo-p-dioxin-like chemicals," Fund. Appl. Toxicol. 30:194-203 (1996).	
		Heathpagliuso, S. et al. "Activation of the Ah receptor by tryptophan and tryptophan metabolites". Biochem. 37(33):11508-11515 (1998).	
		Lee, I. J. et al. "Transcriptional induction of the cytochrome p4501a1 gene by a thiazolium compound, yh439". Mol. Pharmacol. 49(6):980-988 (1996).	
		Liu, R. M. et al. "Regulation of [Ah] gene battery enzymes and glutathione levels by 5,10-dihydroindeno[1,2-b]indole in mouse hepatoma cell lines". Carcinogenesis. 15(10):2347-2352. (1994).	
		Poellinger, L. "Mechanistic aspects-the dioxin (aryl hydrocarbon) receptor". Food Add. Contam. 17(4):261-266 (2000).	
		Poland, A. and Glover, E. "Chlorinated dibenzo-p-dioxin: Potent inducers of -aminolevulinic acid synthetase and aryl hydrocarbon hydroxylase. II. A study of the structure-activity relationship". Mol. Pharmacol. 9:736-747 (1973).	
GS		Rannung, A. et al. "Certain photooxidized derivatives of tryptophan bind with very high affinity to the Ah receptor and are likely to be endogenous signal substances," J. Biol. Chem. 262:15422-15427 (1987).	

Examiner Signature		Date Considered	1/30/05
--------------------	--	-----------------	---------

<sup>1</sup> EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



